Saturday, October 31, 2026

Brazilian fintechs deploy AI credit models to accelerate growth while holding risk margins steady

Nu Holdings pushed its nuFormer AI model to production in 2025 and launched 100+ products while keeping risk-adjusted margins stable quarter-over-quarter. Inter & Co added 7 million clients in 2025—its best year ever—with new cohorts transacting faster than older users, as AI-driven underwriting reshapes fintech economics.

Brazilian fintechs deploy AI credit models to accelerate growth while holding risk margins steady
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Nu Holdings deployed its nuFormer AI credit model to production in 2025, enabling the fintech to launch more than 100 products and features across markets while maintaining stable risk-adjusted net interest margins quarter-over-quarter. The deployment demonstrates how AI-driven underwriting allows rapid expansion without proportional increases in credit losses.

Inter & Co welcomed 7 million new clients in 2025, marking its strongest annual performance. The fintech maintains industry-leading funding costs at 65.6% of CDI, Brazil's benchmark interbank rate. Inter's newer client cohorts are transacting faster and more frequently than older cohorts, suggesting AI models improve client quality at acquisition.

Traditional credit underwriting requires manual review of documents, income verification, and subjective risk assessment. This process takes days and limits portfolio growth to the pace of human reviewers. AI models analyze hundreds of data points in seconds, including transaction patterns, payment history, and behavioral signals invisible to manual processes.

Real-time portfolio monitoring represents the second advantage. AI systems flag deteriorating credit conditions before they materialize as losses, allowing lenders to adjust terms or suspend credit lines proactively. Traditional systems rely on monthly reviews, creating lag between risk emergence and response.

The technology enables client acquisition cost optimization. Automated decisioning reduces underwriting expenses per application while improving approval accuracy. Higher approval rates for creditworthy applicants increase conversion, while better rejection of risky applicants reduces future losses. Both effects improve unit economics.

Nu's stable margins despite rapid product expansion suggest AI models maintain credit discipline under growth pressure. Manual underwriting teams often lower standards when acquisition targets rise. Algorithmic decisioning applies consistent criteria regardless of volume.

The competitive gap widens between AI-equipped fintechs and traditional banks. Incumbents carry legacy systems designed for branch-based lending and batch processing. Retrofitting AI requires replacing core infrastructure, a multi-year project. Neobanks built cloud-native architectures from inception, allowing rapid model deployment.

Inter's cohort performance data indicates AI models identify higher-quality borrowers at onboarding. Faster transaction velocity among new clients suggests they carry better credit profiles and higher engagement levels. This selection effect compounds over time as portfolio composition shifts toward AI-screened borrowers.

Brazilian fintechs now process millions of credit decisions monthly through automated systems, a scale impossible with human underwriters. The technology transforms credit from a scarce, manually rationed resource into a dynamic product that scales with demand while maintaining risk parameters.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com